IPM Take
Europe’s next cardiovascular intervention may not begin in a cath lab.
It may begin with a blood-pressure cuff, a cholesterol test and a conversation years before the first symptom appears.
The European Commission’s proposed Council Recommendation on cardiovascular health checks marks a significant shift in how the EU is approaching its biggest cause of death. Rather than concentrating prevention primarily on people already known to be at high cardiovascular risk, the proposal sets out a life-course framework for identifying risk earlier and connecting detection to follow-up care.
The distinction matters.
Europe does not lack knowledge about hypertension, high LDL cholesterol, diabetes or obesity. It lacks consistent detection and treatment of those risks across countries, regions and population groups.
The proposal tries to make that gap a policy problem rather than an individual one.
It recommends at least one cardiovascular health check before age 35, systematic checks at least every five years for people aged 35 to 64, and checks every three to five years from age 65. The content becomes more intensive with age and risk, incorporating measures ranging from blood pressure and lipids to kidney function, HbA1c, Lp(a) and, for older adults, potential ECG, natriuretic peptide and atrial fibrillation assessment.
But this is not a call for indiscriminate mass screening.
The Commission explicitly recognises that targeted approaches focused on higher-risk populations may be more cost-effective than universal population checks, and leaves Member States considerable room to adapt programmes to local epidemiology, workforce capacity and health-system structure.
That flexibility will be essential.
Finding risk is the easy part.
Europe’s real test will be whether a positive health check leads to diagnosis, treatment and long-term prevention rather than simply another number entered into a medical record.
Executive Summary
The European Commission adopted a proposal for a Council Recommendation on cardiovascular health checks as part of the implementation of its Safe Hearts Plan.
The proposal sets out a common EU direction for earlier detection while leaving programme design and delivery largely to national and regional authorities.
Its proposed life-course model distinguishes three broad groups.
For people under 35, Member States are invited to consider at least one cardiovascular health check, including behavioural risk assessment, blood pressure, glucose, kidney function and body mass index, with additional evaluation where family history or other risk factors indicate higher risk.
For adults aged 35 to 64, the Commission proposes systematic cardiovascular health checks at least every five years, with frequency adapted according to individual and local risk. The suggested assessment includes blood pressure, full lipid profile, fasting glucose and HbA1c, kidney function, BMI, waist measurements, lifestyle factors and a once-in-adulthood Lp(a) measurement.
For people aged 65 and older, checks would generally occur every three to five years, with additional consideration of ECG, natriuretic peptide testing, pulse assessment for atrial fibrillation, cardiopulmonary examination and peripheral artery disease assessment where appropriate.
The proposal also sets population-level ambitions for routine measurement of major risk factors. These include annual blood-pressure measurement for at least 75% of adults aged 25 to 64 and 90% of people aged 65 and older, alongside similarly ambitious targets for cholesterol and blood glucose testing.
The initiative sits within the EU Safe Hearts Plan, launched in December 2025, which aims to reduce premature cardiovascular mortality by 25% by 2035.
The legislative status is important: this is currently a Commission proposal for a Council Recommendation, not an adopted binding EU requirement. The Council procedure is ongoing, and even an adopted Council Recommendation would guide and coordinate Member States rather than operate like directly applicable EU legislation.
Why it matters
- HTA bodies: Earlier detection could significantly expand use of laboratory testing, risk prediction, ECGs and other diagnostics. The policy challenge will be distinguishing tests that change management from those that simply generate more information. Cost-effectiveness is likely to depend heavily on age, baseline risk and what happens after a positive result.
- Payers: The proposal shifts spending upstream. Health systems may need to finance more preventive testing today in return for fewer myocardial infarctions, strokes, heart-failure admissions and other costly events later. That economic case will be strongest where screening is linked to reliable treatment and follow-up.
- Industry / innovation partners: A European move toward structured cardiovascular checks could expand demand for diagnostics, point-of-care testing, digital risk assessment, remote monitoring and AI-supported tools. But the Commission explicitly couples innovation with responsible use, human oversight and integration into care pathways, making implementation evidence as important as technical performance.
Europe already knows many of the numbers that predict cardiovascular disease.
Blood pressure.
LDL cholesterol.
Blood glucose.
Kidney function.
Waist circumference.
The problem is that millions of people do not know their own.
That is the gap the European Commission is now trying to turn into a coordinated prevention strategy.
On 28 September, it proposed a Council Recommendation on cardiovascular health checks and launched the first EU Screening Week, putting early detection at the centre of the Safe Hearts Plan.
The political message is deceptively simple: find cardiovascular risk before cardiovascular disease finds the patient.
The policy underneath it is considerably more ambitious.
From opportunistic testing to a life-course pathway
Cardiovascular risk has traditionally been detected unevenly.
One patient has their blood pressure checked every few months because they regularly see a general practitioner.
Another goes years without a primary-care visit.
A third discovers high cholesterol only after a relative has a heart attack.
The proposed EU approach attempts to make detection more systematic without prescribing one identical screening programme for 27 health systems.
Rather than setting a single screening age, the Commission proposes a life-course model.
The youngest adults would receive at least one baseline opportunity to identify major risks.
Middle-aged adults would move into structured periodic checks.
Older adults would receive more frequent and potentially more comprehensive assessment as cardiovascular risk increases.
This matters because cardiovascular prevention does not begin at 65.
Atherosclerosis, hypertension, metabolic disease and kidney dysfunction can develop silently for decades before producing an event.
By the time a heart attack becomes the first obvious sign, prevention has arrived late.
The check is becoming broader than cholesterol
The proposed framework is also notable for how much it considers part of cardiovascular risk assessment.
For adults aged 35 to 64, the Commission suggests looking beyond a simple blood-pressure reading and total cholesterol.
The proposed components include a full lipid profile, glucose and HbA1c, kidney function, BMI and waist measurements, family history, reproductive history, mental health, diet, physical activity, nicotine exposure and alcohol consumption.
Lp(a) would be measured once in adulthood.
That reflects a broader change in cardiovascular medicine.
Heart disease is increasingly being approached as part of an interconnected cardiovascular, renal and metabolic system rather than as an isolated problem inside the coronary arteries.
Screening policy is beginning to follow that science.
Europe is not proposing the same check for everyone
The word “screening” can imply that every citizen will be called for the same test at the same age.
That is not what the proposal says.
The Commission explicitly recommends adaptation according to national and regional epidemiology, healthcare resources and workforce capacity.
Risk matters too.
People with a family history of premature cardiovascular disease, sudden cardiac death or other known risk factors may need earlier or more individualised assessment.
The proposal also acknowledges a key economic reality: targeted checks for higher-risk populations may offer better cost-effectiveness than broad population-wide programmes.
That gives Member States significant flexibility.
It also creates the possibility of 27 different interpretations of what sufficient cardiovascular screening looks like.
The EU can establish a direction.
Implementation will remain national.
The most important word may be “follow-up”
There is a danger in any screening policy.
Testing can become the endpoint.
A person receives a blood-pressure reading, cholesterol result or cardiovascular-risk score. The abnormality is recorded. Awareness rises.
Nothing else happens.
The Commission’s proposal repeatedly links health checks with patient-centred follow-up, diagnosis and treatment.
That is crucial.
Hypertension only becomes a preventable cardiovascular risk if elevated blood pressure leads to confirmation, treatment and control.
High LDL cholesterol only becomes actionable if clinical risk is assessed and appropriate lipid-lowering intervention follows.
Diabetes screening matters when diagnosis leads to effective metabolic and cardiovascular management.
The success metric therefore cannot simply be the percentage of Europeans tested.
It needs to include what happened next.
Equity is built into the proposal
The Commission also recognises that people least likely to receive preventive care may be among those who need it most.
The proposal specifically identifies rural communities, migrants, socioeconomically disadvantaged populations, people with disabilities and those living with multiple conditions as groups requiring attention.
That is why delivery is not restricted to conventional clinics.
Community settings, pharmacies, workplaces, mobile screening units and opportunistic testing when people encounter the healthcare system could all contribute.
This is potentially one of the proposal’s most consequential elements.
A prevention strategy based only on people voluntarily booking an appointment may preferentially reach citizens who are already more engaged with healthcare.
A strategy that goes to communities could reach a very different population.
But outreach creates another obligation.
A mobile unit can discover hypertension in minutes.
It cannot manage hypertension for the next 20 years.
The connection back into primary care becomes essential.
AI enters prevention, but not alone
The Commission also leaves space for data-driven and artificial-intelligence tools in cardiovascular risk assessment.
That could include better risk stratification, identification of high-risk individuals and more personalised prevention.
But the proposal is careful not to position AI as an autonomous gatekeeper.
Responsible use and appropriate human oversight are explicitly part of the framework.
That is important because screening is uniquely sensitive to algorithmic design.
A model that performs differently across sex, ethnicity, socioeconomic groups or national populations could systematically determine who receives additional investigation and who does not.
As AI moves earlier into the cardiovascular pathway, validation will need to focus not only on prediction accuracy but on who benefits from the decisions the model generates.
The workforce problem cannot be screened away
There is also a practical contradiction at the heart of the strategy.
Finding more cardiovascular risk creates more work.
More abnormal blood-pressure measurements mean more confirmatory assessments.
More elevated cholesterol means more prescribing and follow-up.
More atrial fibrillation detection creates anticoagulation decisions.
More high-risk patients require counselling, monitoring and sometimes specialist referral.
Europe is trying to expand prevention while many health systems are already struggling with shortages in primary care and specialist capacity.
The Commission recognises this by asking Member States to consider healthcare resources and workforce when designing programmes.
That caveat may determine whether the proposal succeeds.
A health check without capacity for follow-up risks becoming surveillance rather than prevention.
EU Screening Week is the visible part of a much bigger strategy
The first EU Screening Week, running from 28 September to 4 October, gives the policy a public-facing dimension.
Events across Europe are encouraging people to “Know Your Numbers”, with blood-pressure, lipid and glucose testing forming the core message.
The accompanying campaign will continue through 2027.
Those awareness activities are useful.
But the proposal itself goes substantially beyond a public-health campaign.
It is attempting to establish common expectations for how cardiovascular risk should be detected across the European life course.
That means governance.
Data collection.
Workforce.
Clinical pathways.
Risk stratification.
Digital infrastructure.
Follow-up.
And eventually, measurement of whether any of it prevented disease.
Europe is setting a target. Member States still have to build the system
The Commission’s ultimate target is substantial: a 25% reduction in premature cardiovascular mortality by 2035.
Health checks alone will not deliver that.
Tobacco control, nutrition, physical activity, obesity prevention, diabetes treatment, lipid management, hypertension control, vaccination and access to effective cardiovascular treatment all remain part of the picture.
But health systems cannot manage a risk they have never detected.
That is why this proposal matters.
The EU is effectively arguing that cardiovascular prevention should become an organised pathway rather than something that happens only when a patient happens to encounter the right clinician at the right time.
The proposal is still moving through the Council.
The harder stage comes after political agreement.
Europe does not need to prove that measuring blood pressure can identify hypertension. It needs to prove that a continental push to find cardiovascular risk earlier can reliably turn detection into prevention.
